Small study tests drug interaction in advanced cancer patients
NCT ID NCT05072106
First seen Nov 01, 2025 · Last updated May 11, 2026 · Updated 31 times
Summary
This study looked at how bosentan, a drug that affects liver enzymes, changes the way the body processes the cancer drug lurbinectedin. It involved 11 adults with advanced solid tumors who had no other treatment options. The goal was to measure drug levels in the blood to understand the interaction, not to treat the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fundación Jiménez Diaz
Madrid, 28040, Spain
-
Hospital de Sanchinarro
Madrid, 28050, Spain
Conditions
Explore the condition pages connected to this study.